Literature DB >> 8129746

Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.

S W Johnson1, R P Perez, A K Godwin, A T Yeung, L M Handel, R F Ozols, T C Hamilton.   

Abstract

A series of cisplatin-resistant cell lines were used to examine the formation and removal of platinum-DNA adducts from the overall genome and the formation and removal of cisplatin-interstrand cross-links from specific genomic regions. Cisplatin accumulation and DNA platination levels, which correlated linearly, were similar in three of the resistant cell lines despite differences in their primary cisplatin resistance. Increased platinum removal from total genomic DNA was found to be associated with increased resistance. Interstrand cross-link levels were found to be 2- to 4-fold lower in the 28S ribosomal RNA gene and a non-coding genomic region of the resistant cell lines as compared with the parental A2780 cell line. In addition, 1.2- to 2.7-fold more cross-links were formed in the non-coding region than in the ribosomal RNA gene in all of the cell lines. Interstrand cross-links were removed more rapidly from both regions of the highly cisplatin-resistant C80 and C200 cells and from the ribosomal RNA gene only in the cell lines of lower resistance. The results support a role for DNA repair and alterations in interstrand cross-link formation in cisplatin resistance and provide evidence for heterogeneous interstrand cross-link formation in the genome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8129746     DOI: 10.1016/0006-2952(94)90132-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  24 in total

1.  Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.

Authors:  Xiao-Qin Li; Jin Ren; Ping Chen; Yu-Jiao Chen; Min Wu; Yan Wu; Kang Chen; Jian Li
Journal:  Acta Pharmacol Sin       Date:  2018-05-31       Impact factor: 6.150

2.  Cypripedin, a phenanthrenequinone from Dendrobium densiflorum, sensitizes non-small cell lung cancer H460 cells to cisplatin-mediated apoptosis.

Authors:  Onsurang Wattanathamsan; Surassawadee Treesuwan; Boonchoo Sritularak; Varisa Pongrakhananon
Journal:  J Nat Med       Date:  2018-02-09       Impact factor: 2.343

Review 3.  Biomarkers of head and neck cancer, tools or a gordian knot?

Authors:  Evangeli S Lampri; Georgios Chondrogiannis; Elli Ioachim; Anna Varouktsi; Antigoni Mitselou; Aggeliki Galani; Evangelos Briassoulis; Panagiotis Kanavaros; Vasiliki Galani
Journal:  Int J Clin Exp Med       Date:  2015-07-15

4.  PEGylated multi-walled carbon nanotubes for encapsulation and sustained release of oxaliplatin.

Authors:  Linlin Wu; Changjun Man; Hong Wang; Xiaohe Lu; Qinghai Ma; Yu Cai; Wanshan Ma
Journal:  Pharm Res       Date:  2012-09-20       Impact factor: 4.200

5.  Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer.

Authors:  Akaash K Mishra; Silvana S Dormi; Alaina M Turchi; Derek S Woods; John J Turchi
Journal:  Biochem Pharmacol       Date:  2014-11-04       Impact factor: 5.858

6.  Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.

Authors:  Ganna V Kalayda; Bart A J Jansen; Peter Wielaard; Hans J Tanke; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2005-04-12       Impact factor: 3.358

7.  Disruption of mouse SNM1 causes increased sensitivity to the DNA interstrand cross-linking agent mitomycin C.

Authors:  M L Dronkert; J de Wit; M Boeve; M L Vasconcelos; H van Steeg; T L Tan; J H Hoeijmakers; R Kanaar
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

8.  Genome-wide single-nucleotide resolution of oxaliplatin-DNA adduct repair in drug-sensitive and -resistant colorectal cancer cell lines.

Authors:  Courtney M Vaughn; Christopher P Selby; Yanyan Yang; David S Hsu; Aziz Sancar
Journal:  J Biol Chem       Date:  2020-04-16       Impact factor: 5.157

9.  DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.

Authors:  Sham S Kakar; Christopher A Worth; Zhenglong Wang; Kelsey Carter; Mariusz Ratajczak; Pranesh Gunjal
Journal:  J Cancer Stem Cell Res       Date:  2016-04-19

10.  Monofunctional and higher-valent platinum anticancer agents.

Authors:  Timothy C Johnstone; Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-06-05       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.